Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
Interventions: Strontium L-lactate; Dietary Supplement
Lead sponsor: BioLink Life Sciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Nasogastric Tube Placement
Interventions: Nasotrak System; Device
Lead sponsor: Nasotrak Medical Pte Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Fort Wayne, Indiana • New York, New York

Conditions: Cancer of Head and Neck
Interventions: Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM); Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vaginitis, Dyspareunia, Breast Neoplasms
Interventions: Testosterone propionate; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Burlington, Vermont

Conditions: Type II Diabetes, Periodontal Disease
Interventions: Triclosan containing toothpaste, Non-triclosan containing toothpaste; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
Interventions: Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD); Device · Drug
Lead sponsor: Nuwellis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 38
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Down Syndrome
Interventions: Donepezil HCl, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Intraventricular Hemorrhage, Subarachnoid Hemorrhage
Interventions: CerebroFlo™ EVD Catheter; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Loma Linda, California • Palo Alto, California • Aurora, Colorado + 7 more

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Diabetes Mellitus, Type 2
Interventions: Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 70
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more

Conditions: Alpha1-antitrypsin Deficiency
Interventions: GLASSIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging Testing, Echocardiography Test, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoblastic Lymphoma
Interventions: Vincristine, Radiation Therapy, Daunomycin, L-Asparaginase, Cytarabine, Methotrexate, Mercaptopurine, Etoposide, Cyclophosphamide, Prednisone, Dexamethasone; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2004
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions: Standard of Care, EPIEFFECT, EPIXPRESS; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Uveal Melanoma
Interventions: AVASTIN; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors
Interventions: GO-203-2c; Drug
Lead sponsor: Genus Oncology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: Heart Failure
Interventions: sc2Wear Furosemide Infusor; Combination Product
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Bilateral Renal Agenesis
Interventions: Amnioinfusion; Other
Lead sponsor: Fetal Care Center, PLLC; Industry
Eligibility: Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Relapsed Multiple Myeloma
Interventions: ATRA, Celecoxib, Itraconazole; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Stage IA Non-small Cell Lung Cancer, Lung Carcinoid Tumor
Interventions: Active Surveillance; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions: Zofin, Placebo; Biological · Other
Lead sponsor: ZEO ScientifiX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Ileus, Gastrointestinal Dysfunction
Interventions: Alvimopan; Drug
Lead sponsor: Scott Steele; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body.

Effects of Oral Cancer Treatments on Upper Esophageal Opening During Swallowing

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

Periodontal Treatment Response in Type II Diabetic Patients

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of Intraventricular Hemorrhage (IVH)

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

Treatment With Intravitreal Avastin for Large Uveal Melanomas

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload

Amnioinfusion for Fetal Renal Failure

ATRA, Celecoxib, and Itraconazole as Maintenance

Active Surveillance in Early Lung Cancer

Zofin (Organicell Flow) for Patients With COVID-19

Alvimopan as a Rescue Treatment of Postoperative Ileus

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma